Let me indulge in copying (for a good purpose) and
Post# of 155150
(Total Views: 876)
Posted On: 04/26/2020 3:55:02 PM
Let me indulge in copying (for a good purpose) and old post of mine:
Well, now we got some data from the 5 patients that got it under compassionate use. These patients had several comorbidities and where in very bad shape. Below some published values.
CYTOKINE PROFILES (pg/mL) OF 5 PATIENTS TREATED WITH LERONLIMAB (BEFORE
AND 3 DAYS AFTER ADMINISTRATION).
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Day 0 Day 3 Day 0 Day 3 Day 0 Day 3 Day 0 Day 3 Day 0 Day 3
IL-6 1000.1 344.2 522.6 122.1 2506.6 214.1 8175.1 2021.5 83 36.8
IL-9 <2.2 <2.2 1.8 1 1.8 1.9 33.2 58.3 1.9 2.3
IL-10 <1.9 7.7 3 2.7 <0.9 1.4 <0.9 1.3 1.3 4.9
IFN-γ <5.8 6.9 <1.7 <1.7 <1.7 <1.7 3.6 <1.7 <1.7 <1.7
TNF-α 8.48 <8.2 1.4 1.2 <1.7 <1.7 <1.7 <1.7 <1.7 <1.7
So, we have IL-6 reductions for these 5 patients of 65.%, 76.6%, 91.46%, 75.27%, 55.55% respectively after 3 days (59.8% average) with the usage of Leronlimab !!!
No wonder Dr Patterson was so entusiastic and mentioned the reductions of 70%.
A. Fuerstein should read these numbers instead of mouth-fouling Leronlimab and comment on them before talking nonsense. This is the case (repeating myself again) where he sees Leronlimab walking on waters and he says " look !! Leronlimab doesn't know how to swim …"
Let me repeat some facts: when administered to severely ill patients with various comorbidities, Leronlimab reduced in three days the level of IL-6, an excellent mortality predictor for CAP, on average 59.8%.
Now I would like to know what these number would look like 7 days and latter on, but for sure they where going in the right direction very rapidly.
Additionally (from an other source) :
Again, other of Dr. Patterson findings where he expressed that for the horribly immunosuppressed patients in NY: "They all responded in similar manner, we are seeing a restoration of their immune systems in 3 days and almost full recovery after 7 days and this is I addition to quieting the quieting cytokine storm so it basically two mechanisms at play here, the immunosuppression makes them susceptible to other infractions."
Also, in addressing the recent findings with clogging and myocardial complications (from another source):
This very first numbers are an irrefutable indication of the effect of Leronlimab. More ill come no doubt in the NEJM, can't wait.
Quote:
According to Dr. B. Patterson: Off therapy patients showed profound immunological disturbances. Plasma so elevated causing tissue damage in the long. After 3 days with Leronlimab Immunological correction restored to normal with a large (70%) decrease of IL-6, also TNF-alpha decreased.
This, for me, is the most important part of the last interactive interview (of course apart from learning the shape of the patients in general).
So, what is the meaning of a substantial reduction on IL-6 (Interleukin-6) as far as COVID goes??. Well, I think COVID is so new that not much research exists in the subject.
However, there is some research on a similar indication, Community acquired pneumonia (CAP). At the end stages of COVID the patients are suffering effects similar to pneumonia which is nothing else that a viral (or bacterial) lung inflammation. This condition is very deadly: hospitalized CAP patients with elevated IL-6 level have a 93.4% higher risk level for lethal outcome. The 101 patients enrolled in this trial, 76 (75.2%) males and 25 (24.8%) females. The average age of the enrolled patients was 63.7 ± 11.8 years. This is very similar to what we are having now with COVID.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073574/
IL-6 production is initiated by inflammatory reaction induced by trauma, stress and infection. IL-6 has much longer plasma half-life than other pro-inflammatory cytokines, and that is why IL-6 serves as a very useful marker of pro-inflammatory cytokine activation. Several studies found positive correlation between serum IL-6 concentration at admission and endmost mortality in CAP. IL6 was shown to have independent predictive value in CAP mortality.
The conclusions: Based on ROC (receiver operating characteristic) curve analysis (AUC ± SE = 0.934 ± 0.035; 95%CI (0.864-1.0); P = 0.000) hospitalized CAP patients with elevated IL-6 level have 93.4% higher risk level for lethal outcome. As a predictor of mortality at the cut-off value of 20.2 pg/ml IL-6 shows sensitivity of 84% and specificity of 87%.
Bottom line: for CAP the levels of IL-6 predict the mortality rate pretty damn well. If this is the case for COVID as well (until today, I don’t think anybody knows this for certain) the reduction of 70% on IL-6 achieved by Leronlimab is a life saver with no questions about it. It would be nice to learn to what level these values where reduced (a normal male has a value of 0 – 3.5 pg/ml in plasma) .
Well, now we got some data from the 5 patients that got it under compassionate use. These patients had several comorbidities and where in very bad shape. Below some published values.
CYTOKINE PROFILES (pg/mL) OF 5 PATIENTS TREATED WITH LERONLIMAB (BEFORE
AND 3 DAYS AFTER ADMINISTRATION).
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Day 0 Day 3 Day 0 Day 3 Day 0 Day 3 Day 0 Day 3 Day 0 Day 3
IL-6 1000.1 344.2 522.6 122.1 2506.6 214.1 8175.1 2021.5 83 36.8
IL-9 <2.2 <2.2 1.8 1 1.8 1.9 33.2 58.3 1.9 2.3
IL-10 <1.9 7.7 3 2.7 <0.9 1.4 <0.9 1.3 1.3 4.9
IFN-γ <5.8 6.9 <1.7 <1.7 <1.7 <1.7 3.6 <1.7 <1.7 <1.7
TNF-α 8.48 <8.2 1.4 1.2 <1.7 <1.7 <1.7 <1.7 <1.7 <1.7
So, we have IL-6 reductions for these 5 patients of 65.%, 76.6%, 91.46%, 75.27%, 55.55% respectively after 3 days (59.8% average) with the usage of Leronlimab !!!
No wonder Dr Patterson was so entusiastic and mentioned the reductions of 70%.
A. Fuerstein should read these numbers instead of mouth-fouling Leronlimab and comment on them before talking nonsense. This is the case (repeating myself again) where he sees Leronlimab walking on waters and he says " look !! Leronlimab doesn't know how to swim …"
Let me repeat some facts: when administered to severely ill patients with various comorbidities, Leronlimab reduced in three days the level of IL-6, an excellent mortality predictor for CAP, on average 59.8%.
Now I would like to know what these number would look like 7 days and latter on, but for sure they where going in the right direction very rapidly.
Additionally (from an other source) :
Quote:
Interestingly, the numbers of total T cells, CD4+ T and CD8+ T cells are negatively correlated to levels of TNF-α, IL-6 and IL-10, respectively suggesting these cytokines promote T cells decrease in COVID-19 patients.
Again, other of Dr. Patterson findings where he expressed that for the horribly immunosuppressed patients in NY: "They all responded in similar manner, we are seeing a restoration of their immune systems in 3 days and almost full recovery after 7 days and this is I addition to quieting the quieting cytokine storm so it basically two mechanisms at play here, the immunosuppression makes them susceptible to other infractions."
Also, in addressing the recent findings with clogging and myocardial complications (from another source):
Quote:
Exaggerated, excessive synthesis of IL-6 while fighting environmental stress leads to an acute severe systemic inflammatory response known as ‘cytokine storm’, since high levels of IL-6 can activate the coagulation pathway and vascular endothelial cells but inhibit myocardial function.
This very first numbers are an irrefutable indication of the effect of Leronlimab. More ill come no doubt in the NEJM, can't wait.
(13)
(0)